Creative Financial Designs Inc. ADV Purchases 2,023 Shares of Pfizer Inc. (NYSE:PFE)

Creative Financial Designs Inc. ADV boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 44,882 shares of the biopharmaceutical company’s stock after buying an additional 2,023 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Pfizer were worth $1,191,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the 4th quarter valued at $31,000. Finally, Sierra Ocean LLC purchased a new position in Pfizer during the 4th quarter valued at $34,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $26.07 on Tuesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company’s 50-day moving average is $26.22 and its 200 day moving average is $27.10. The company has a market capitalization of $147.72 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on PFE shares. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.